A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 4, 2008, Pages 408-413

  Sharpe, Elizabeth D ^a   Williams, Robert D ^b   Stewart, Jeanette A ^c   Nelson, Lindsay A ^d   Stewart, William C ^c,e,f  

^a Glaucoma Consultants   (United States)

^b Taustine Eye Center   (United States)

^c University of South Carolina   (United States)

^d Charleston Research Company LLC   (United States)

^e UNIVERSITY OF SOUTH CAROLINA   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; DORZOLAMIDE PLUS TIMOLOL;

ARTICLE; BIOMICROSCOPY; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; GONIOSCOPY; HUMAN; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; OPHTHALMOSCOPY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; AMIDES; CLOPROSTENOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 48349105843     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0003     Document Type: Article

References (27)

1. Boyle, J.E., Ghosh, K., Gieser, D.K., et al. A randomized trial comparing the dorzolamide-timolol combination given twice-daily to monotherapy with timolol or dorzolamide. Ophthalmology 106:10-16, 1999.
2. Fechtner, R.D., Airaksinen, P.J., Getson, A.J., et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: Results from two randomized, clinical trials. Acta. Ophthalmol. Scand. 82:42-48, 2004.
3. Shin, D.H., Feldman, R.M., and Sheu, W.P. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 111:276-282, 2004.
4. Maxey, K.M., Johnson, J.L., and LaBrecque, J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv. Ophthalmol. 47:S34-S40, 2002.
5. Woodward, D.F., Krauss, A.H., Chen, J., et al. The pharmacology of bimatoprost (Lumigan). Surv. Ophthalmol. 45:S337-S345, 2001.
6. Sherwood, M., Brandt, J., for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol. 45:S361-S368, 2001.
7. Coleman, A.L., Lerner, F., Bernstein, P., et al. A 3-month, randomized, controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 110:2362-2368, 2003.
8. Day, D.G., Sharpe, E.D., Beischel, C.J., et al. Safety and efficacy of bimatoprost 0.03% versus timolol 0.5%/dorzolamide 2% fixed combination. Eur. J. Ophthalmol. 15:336-342, 2005.
9. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol. 130:429-440, 2000.
10. Mao, L.K., Stewart, W.C., and Shields, M.B. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am. J. Ophthalmol. 1991;111:51-55.
11. Stewart, W.C., Chorak, R.P., Hunt, H.H., et al. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am. J. Ophthalmol. 116:176-181, 1993.
12. Stewart, W.C., Kolker, A.E., Sharpe, E.D., et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am. J. Ophthalmol. 130:274-279, 2000.
13. Musch, D.C., Lichter, P.R., Guire, K.E., et al. The Collaborative Initial Glaucoma Treatment Study: Study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 106:653-662, 1999.
14. Stewart, W.C., Chorak, R.P., Hunt, H.H., et al. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am. J. Ophthalmol. 116:176-181, 1993.
15. Konstas, A.G., Papapanos, P., Tersis, I., et al. Twenty-fourhour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 110:1357-1360, 2003.
16. Orzalesi, N., Rossetti, L., Bottoli, A., et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch. Ophthalmol. 121:453-457, 2003.
17. Noecker, R.S., Dirks, M.S., Choplin, N.T., et al. A six-month, randomized, clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Ophthalmol. 135:55-63, 2003.
18. Parrish, R.K., Palmberg, P., and Sheu, W.P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol. 135:688-703, 2003.
19. Gandolfi, S., Simmons, S.T., Sturm, R., et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv. Ther. 18:110-121, 2001.
20. Konstas, A.G., Katsimbris, J.M., Lallos, N., et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 112:262-266, 2005.
21. Williams, R.D. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv. Ther. 19:275-281, 2002.
22. Wan, Z., Woodward, D.F., Cornell, C.L., et al. Bimatoprost, prostamide activity, and conventional drainage. Invest. Ophthalmol. Vis. Sci. 48:4107-4115, 2007.
23. 2α selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. Exp. Eye Res. 80:135-145, 2005.
24. Romano, M.R., and Lograno, M.D. Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprostinduced contractions on the human isolated ciliary muscle. Invest. Ophthalmol. Vis. Sci. 48:3677-3682, 2007.
25. Stewart, W.C., Day, D.G., Stewart, J.A., et al. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% versus placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye 18:905-910, 2004.
26. Konstas, A.G., Maltezos, A.C., Gandi, S., et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol in patients with primary open-angle glaucoma. Am. J. Ophthalmol. 128:15-20, 1999.
27. Konstas, A.G., Mikropoulos, D., Kaltsos, K., et al. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology 113:446-450, 2006.